Strategies and Pathways Targeting Domains in the Treatment of Psoriatic Disease
Released On
December 19, 2022
Expires On
December 19, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Rheumatology
Topic(s)
Psoriasis
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Paradigm Medical Communications, LLC.
This activity is supported by an educational grant from Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC, and Novartis.
Credit Available
- Physicians — may claim a maximum of 1.0 AMA PRA Category 1 Credit™.
- PA's — may claim a maximum of 1.0 Category 1 credit.
- NP's — may claim a maximum of 1.0 Category 1 credit.
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity has been designed to address the educational needs of rheumatology and dermatology clinicians. It may also be of benefit to other clinicians interested in the care of patients who have psoriatic disease.
Statement of Need/Program Overview
Psoriatic disease is a complex disease in which musculoskeletal and cutaneous inflammation occurs alongside hyperproliferation of both bone and skin. Patients have heterogeneous presentations of disease activity across 6 domains: Psoriasis, peripheral arthritis, enthesitis, dactylitis, spondylitis, and nail disease. Associated inflammatory processes give rise to additional conditions such as uveitis and inflammatory bowel disease, and comorbid metabolic diseases can further complicate disease management. Psoriatic arthritis (PsA) is frequently accompanied by fatigue, pain, and disability that negatively impact quality of life for patients and further challenge effective management. Aggressive targeted treatment started early in the disease process has demonstrated the best patient outcomes. New guidelines are available that provide treatment recommendations but are not concrete algorithms, so clinicians are left to make treatment decisions based on their understanding of agents’ mechanisms of action and personal experience without sufficient data because head-to-head data to inform decisions are lacking. In this roundtable discussion, rheumatologist and dermatologist faculty discuss the pathologic pathways targeted by biologic therapy, and screening to identify PsA in patients with psoriasis early. Cases are used to illustrate the complexities of psoriatic disease management, and as a springboard to show clinical application of recent guideline recommendations for treatment.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the mechanisms of action for targeted agents to treat psoriasis/PsA
- Develop treatment plans for patients with psoriasis/PsA based on clinical evidence, guideline recommendations, and individual disease manifestations and disease activity
- Make appropriate individualized treatment decisions based on assessment of patient phenotypes, disease activity, comorbidities, treatment experience, and preferences
Faculty
Mohamad Bittar, MD
Assistant Professor
College of Medicine
Department of Medicine
Division of Medicine—Rheumatology
The University of Tennessee Health Science Center
Memphis, TN
Alexis Ogdie, MD, MSCE
Associate Professor of Medicine and Epidemiology
Director, Penn Center for Clinical Epidemiology and Biostatistics
Director, Penn Psoriatic Arthritis and Spondyloarthritis Program
Perelman School of Medicine at the University of Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, PA
Cheryl Rosen, MD, FRCPC
Professor, Department of Medicine
University of Toronto
Head, Division of Dermatology
Toronto Western Hospital and University Health Network Hospitals
Toronto, Ontario, Canada
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians
Physician Credit Designation
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nursing Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosures of Conflicts of Interest
- Mohamad Bittar, MD
- Has no relevant financial relationships with ineligible companies to disclose.
- Alexis Ogdie, MD, MSCE
- Consultant: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; CorEvitas; Eli Lilly and Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer Inc.; UCB S.A.
- Research Funding: AbbVie Inc. (paid to Penn); Amgen Inc. (paid to National Databank for Rheumatic Databank); Novartis AG (paid to Penn); Pfizer Inc. (paid to Penn)
- Cheryl Rosen, MD, FRCPC
- Consultant: AbbVie Inc.; Amgen Inc.; Novartis AG; UCB S.A.
Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.
GRAPPA staff reviewer has no relevant financial relationships with ineligible companies to disclose.
Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Instructions for Participation and Credit
To receive a certificate of participation, participants must:
- Follow instructions to register or log in with your professional information and complete the preassessment
- View the online activity in its entirety
- Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment
A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation.
For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.
There are no fees for participating in this activity.
Course Viewing Requirements
Hardware/Software Requirements
This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here:
http://get.adobe.com/reader.
Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Contact Information
If you have any questions or comments, please email us at contactus@paradigmmc.com..